{
    "title": "Pfizer scraps one weight loss drug in race to develop Ozempic rival",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12234215/Pfizer-discontinue-development-obesity-drug.html",
    "date": "2023-06-26",
    "keywords": [
        "obesity",
        "pill",
        "pfizer",
        "danuglipron",
        "lotiglipron",
        "erman",
        "liver",
        "treatment",
        "loss",
        "drug",
        "year",
        "company",
        "wegovy",
        "none",
        "inc",
        "safety",
        "success",
        "trading",
        "monday",
        "therapy",
        "albert",
        "bourla",
        "product",
        "companys",
        "strategy",
        "covid",
        "revenue",
        "index",
        "period",
        "latestage",
        "program",
        "end",
        "release",
        "version",
        "parallel",
        "preference",
        "news",
        "competitor",
        "promising",
        "experimental",
        "truist",
        "analyst",
        "robyn",
        "karnauskas",
        "race",
        "day",
        "formulation",
        "research",
        "note",
        "month",
        "weight",
        "par",
        "midstage",
        "study",
        "brand",
        "demand",
        "decade",
        "industry",
        "evidence",
        "failure",
        "reporting",
        "leo",
        "bengaluru",
        "michael",
        "jersey",
        "editing",
        "pooja",
        "desai",
        "jason",
        "babington"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}